Our proof-of-principle finding with patient-derived models and engineered models demonstrated that RAC1-amplified HNSCC could be pharmacologically vulnerable to Rac inhibitor targeting, both in vitro and in vivo. Here, AKT1 is linked to head and neck squamous cell carcinoma.